{"product_id":"annexonbio-business-model-canvas","title":"Annexon Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnnexon Business Model Canvas: Tactical roadmap for investors, founders, and advisors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Annexon’s business model—this concise Business Model Canvas reveals how the company creates therapeutic value, structures partnerships, and monetizes innovation to scale in biotech. Ideal for investors, advisors, and founders seeking actionable insights, the downloadable Word and Excel files provide a section-by-section map you can adapt for benchmarking or strategy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnnexon relies on global contract research organizations (CROs) to run late-stage trials for ANX005 and ANX007, with CRO-managed sites covering 12+ countries and targeting ~1,200 patients combined by end‑2025 to meet submission timelines. These CROs supply trial infrastructure, centralized data management and monitoring that preserved \u0026gt;98% data completeness in pivotal cohorts—critical for imminent regulatory filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnnexon partners with contract manufacturing organizations (CMOs) to scale production of monoclonal antibodies, shifting from mg-scale lab batches to kg-scale clinical and commercial runs; in 2025 industry CMO fill\/finish capacity expanded ~12% to meet biologics demand. These CMOs uphold Good Manufacturing Practice (GMP) for clinical supply and potential launch, cutting time-to-market and capital spend while supporting projected commercial volumes if lead candidates reach approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with top neurobiology labs and universities (e.g., UCSF, University of Oxford collaborations reported in 2024) keep Annexon at the forefront of complement-system research, yielding 3+ biomarker candidates since 2022 and supporting C1q inhibition validation in Alzheimer’s and AMD models; these ties also grant access to single-cell omics platforms and a pipeline of PhD\/postdoc talent, cutting preclinical lead times by an estimated 20%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnnexon partners with Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) patient groups to align R\u0026amp;D with patient needs, improve education, and reduce pivotal-trial enrollment time—GBS advocacy networks supported ~20% faster recruitment in recent neurology trials (2023–2024), while GA registries reached 15,000+ patients by 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAligns development to patient priorities\u003c\/li\u003e\n\u003cli\u003eSpeeds recruitment ~20% in neurology trials\u003c\/li\u003e\n\u003cli\u003eAccess to 15,000+ GA registry patients\u003c\/li\u003e\n\u003cli\u003eImproves caregiver-facing value propositions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpstrategic co-development or licensing deals with big pharmas give annexon funding and global commercialization reach by q4 mid biotech averaged up-fronts of total deal values reducing launch capital risk for first assets.\u003e\n\u003cpthese partners add global distribution and marketing scale annexon lacks speeding market access often covering\u003e60% of commercialization costs in partnered neurology programs.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUp-fronts: $50–150M\u003c\/li\u003e\n\u003cli\u003eTotal deal value: $1–3B\u003c\/li\u003e\n\u003cli\u003eCommercial cost coverage: \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003eTarget timing: alliances by late 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pstrategic\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnnexon's partner ecosystem accelerates trials, supply, funding \u0026amp; commercial readiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnnexon leverages CROs (12+ countries, ~1,200 patients by end‑2025, \u0026gt;98% data completeness), CMOs (kg‑scale GMP supply; 2025 fill\/finish +12% capacity), academic partners (UCSF, Oxford; 3+ biomarkers since 2022, ~20% faster preclinical lead times), patient groups (15,000+ GA registry; ~20% faster neurology recruitment), and pharma deals (up‑front $50–150M; total $1–3B; \u0026gt;60% commercial cost coverage).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2025 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003e12+ countries; ~1,200 pts; \u0026gt;98% data\u003c\/td\u003e\n\u003ctd\u003eRegulatory readiness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003ekg‑scale; fill\/finish +12%\u003c\/td\u003e\n\u003ctd\u003eSupply \u0026amp; launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e3+ biomarkers since 2022\u003c\/td\u003e\n\u003ctd\u003eFaster R\u0026amp;D ~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003e15,000+ GA registry\u003c\/td\u003e\n\u003ctd\u003eRecruitment +20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma partners\u003c\/td\u003e\n\u003ctd\u003eUp‑front $50–150M; $1–3B total\u003c\/td\u003e\n\u003ctd\u003eCost coverage \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, ready-to-use Business Model Canvas for Annexon detailing customer segments, value propositions, channels, revenue streams, key activities, partners, resources, cost structure, and metrics, with insights on competitive advantages and linked SWOT analysis to support presentations, investor discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Annexon’s therapeutic strategy into a digestible one-page snapshot, saving hours of structuring while enabling quick team collaboration and side-by-side comparisons.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvancing lead candidates through Phase 2 and Phase 3 trials, Annexon focuses on rigorous data collection, continuous patient monitoring, and statistical analysis to meet FDA and EMA standards; Phase 3 programs typically cost $100–300M and take 3–5 years, so successful readouts materially drive valuation. Successful trial outcomes are the single largest value inflection—positive Phase 3 results can double or triple market cap, while failures often wipe out most equity value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery and Platform Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnnexon refines its proprietary C1q-inhibition platform to expand indications, adding 3 new target programs in 2024 and aiming for 8 total by 2026; this keeps the pipeline robust and supports follow-on licensing. Research teams optimize antibody delivery and dosing—2024 preclinical PK\/PD studies cut effective dose by 35%, improving projected peak sales per asset in model scenarios by ~$400M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Filing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnnexon must navigate FDA, EMA and other regulators, preparing Biologics License Applications (BLA) and holding regular scientific advice meetings to align trial designs with approval criteria; filing for lead programs is targeted for completion by end-2025. Regulatory spend is budgeted at ~$45–60M through 2025 per program, and prior FDA meetings reduced major review risks from 38% to ~22% in analogous neuro-immunology submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnnexon secures long-term exclusivity by filing patents for novel molecules, formulations, and methods; as of Dec 31, 2025 the company lists 22 issued patents and 40 pending applications covering complement-pathway therapeutics, reducing competitor entry risk and supporting licensing revenue potential.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22 issued patents (to 12\/31\/2025)\u003c\/li\u003e\n\u003cli\u003e40 pending applications\u003c\/li\u003e\n\u003cli\u003ePatents cover molecules, formulations, methods\u003c\/li\u003e\n\u003cli\u003eStrengthens licensing and valuation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and CMC Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnnexon fortifies its CMC (chemistry, manufacturing, controls) to meet FDA\/EMA standards, converting lab syntheses to commercial batches while targeting batch-to-batch impurity \u0026lt;0.5% and stability shelf-lives ≥24 months; these steps cut regulatory delay risks and support Phase 3 readiness.\u003c\/p\u003e\n\u003cp\u003eThey run scale-up studies, stability and release testing on GMP lots, and supplier qualification—over 50 process validation runs planned before BLA\/NDA filing to ensure purity, potency, and consistency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget impurity \u0026lt;0.5%\u003c\/li\u003e\n\u003cli\u003eStability ≥24 months\u003c\/li\u003e\n\u003cli\u003e≥50 validation runs before filing\u003c\/li\u003e\n\u003cli\u003eGMP commercial-scale transfer\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance C1q pipeline to Phase 3: 8 programs by 2026, 62 patents\/applications, Phase 3 = $100–300M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvance lead candidates through Phase 2\/3 with rigorous data capture and patient monitoring; Phase 3 costs $100–300M and 3–5 years, with positive readouts often doubling market cap. Expand C1q platform (3 new targets in 2024; target 8 by 2026), with 22 issued patents and 40 pending (to 12\/31\/2025); CMC targets impurity \u0026lt;0.5%, stability ≥24 months, ≥50 validation runs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 cost\u003c\/td\u003e\n\u003ctd\u003e$100–300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 duration\u003c\/td\u003e\n\u003ctd\u003e3–5 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew targets (2024)\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget programs by 2026\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued patents (12\/31\/2025)\u003c\/td\u003e\n\u003ctd\u003e22\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePending applications\u003c\/td\u003e\n\u003ctd\u003e40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget impurity\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStability\u003c\/td\u003e\n\u003ctd\u003e≥24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation runs\u003c\/td\u003e\n\u003ctd\u003e≥50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the exact Annexon Business Model Canvas you’ll receive after purchase—no mockup, no sample pages—just the real, fully formatted deliverable shown. Upon completing your order, you’ll instantly download this same file, ready to edit, present, and apply in Word and\/or Excel with all sections and content included. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749307691385,"sku":"annexonbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/annexonbio-business-model-canvas.png?v=1772213972","url":"https:\/\/matrixbcg.com\/products\/annexonbio-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}